Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanwei Zhang

Showing results (171-180 of 339) with videos related to

Pageof 34
Sort By:
The Journal of Thoracic and Cardiovascular Surgery|December 11, 2017
Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinomaFangfei Qian, Wenjia Yang, Rui Wang, et al.
International Journal of Cancer|December 23, 2016
Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non-small-cell lung cancer patients with EGFR mutationsYanwei Zhang, Jianlin Xu, Yuqing Lou, et al.
Thoracic Cancer|March 23, 2019
First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in ChinaQing Chang, Yanwei Zhang, Jianlin Xu, et al.
Frontiers in Immunology|March 3, 2022
Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung CancerZhengyu Yang, Ya Chen, Yanan Wang, et al.
Frontiers in Oncology|May 3, 2021
Pembrolizumab Plus Chemotherapy or Anlotinib <i>vs.</i> Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLCYa Chen, Zhengyu Yang, Yanan Wang, et al.
Toxics|September 27, 2024
Health Risk Assessment of Heavy Metals in Agricultural Soils Based on Multi-Receptor Modeling Combined with Monte Carlo SimulationYundong Wu, Yan Xia, Li Mu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|November 28, 2024
Photothermal Synergistic Hydrogen Production via a Fly-Ash-made Interfacial Vaporific SystemYin Xie, Chenyu Xu, Yan Liu, et al.
Veterinary Research|February 25, 2025
HnRNPC triggers the degradation of MITA to suppress the interferon-mediated antiviral responseYanwei Zhang, Zhao Jia, Gaoliang Yuan, et al.
Frontiers in Medicine|February 17, 2022
Removing Clinical Motion Artifacts During Ventilation Monitoring With Electrical Impedance Tomography: Introduction of Methodology and Validation With Simulation and Patient DataLin Yang, Shuoyao Qu, Yanwei Zhang, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 1, 2021
A biotin-avidin-system-based virus-mimicking nanovaccine for tumor immunotherapyZhuoxuan Lu, Yanwei Zhang, Yi Wang, et al.
Pageof 34

Showing results (171-180 of 339) with videos related to

Sort By:
Pageof 34
The Journal of Thoracic and Cardiovascular Surgery|December 11, 2017
Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinomaFangfei Qian, Wenjia Yang, Rui Wang, et al.
International Journal of Cancer|December 23, 2016
Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non-small-cell lung cancer patients with EGFR mutationsYanwei Zhang, Jianlin Xu, Yuqing Lou, et al.
Thoracic Cancer|March 23, 2019
First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in ChinaQing Chang, Yanwei Zhang, Jianlin Xu, et al.
Frontiers in Immunology|March 3, 2022
Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung CancerZhengyu Yang, Ya Chen, Yanan Wang, et al.
Frontiers in Oncology|May 3, 2021
Pembrolizumab Plus Chemotherapy or Anlotinib <i>vs.</i> Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLCYa Chen, Zhengyu Yang, Yanan Wang, et al.
Toxics|September 27, 2024
Health Risk Assessment of Heavy Metals in Agricultural Soils Based on Multi-Receptor Modeling Combined with Monte Carlo SimulationYundong Wu, Yan Xia, Li Mu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|November 28, 2024
Photothermal Synergistic Hydrogen Production via a Fly-Ash-made Interfacial Vaporific SystemYin Xie, Chenyu Xu, Yan Liu, et al.
Veterinary Research|February 25, 2025
HnRNPC triggers the degradation of MITA to suppress the interferon-mediated antiviral responseYanwei Zhang, Zhao Jia, Gaoliang Yuan, et al.
Frontiers in Medicine|February 17, 2022
Removing Clinical Motion Artifacts During Ventilation Monitoring With Electrical Impedance Tomography: Introduction of Methodology and Validation With Simulation and Patient DataLin Yang, Shuoyao Qu, Yanwei Zhang, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 1, 2021
A biotin-avidin-system-based virus-mimicking nanovaccine for tumor immunotherapyZhuoxuan Lu, Yanwei Zhang, Yi Wang, et al.
Pageof 34